Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Seres Therapeutics Inc
(NQ:
MCRB
)
1.130
+0.080 (+7.62%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Seres Therapeutics Inc
< Previous
1
2
3
4
5
Next >
Why Seres Therapeutics Stock Is Crashing Today
July 22, 2021
The company reported disappointing results from a phase 2b clinical study.
Via
The Motley Fool
Mid-Morning Market Update: Markets Mostly Lower; AT&T Beats Q2 Estimates
July 22, 2021
Following the market opening Thursday, the Dow traded down 0.24% to 34,715.42 while the NASDAQ rose 0.13% to 14,651.19. The S&P also fell, dropping 0.08% to 4,355.29. The U.S...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO
July 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) Biohaven Pharmaceutical...
Via
Benzinga
Exposures
Product Safety
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
May 01, 2021
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...
Via
Benzinga
Exposures
Product Safety
Seres Therapeutics Stock Plunges As Ulcerative Colitis Candidate Disappoints In Mid-Stage Study
July 22, 2021
Seres Therapeutics Inc (NASDAQ: MCRB) has announced topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis...
Via
Benzinga
Nestlé Bets $525M On Seres Therapeutics Microbiome Drug For Infectious Diseases
July 01, 2021
Seres Therapeutics Inc (NASDAQ: MCRB) has inked a $525-million deal with Nestlé Health Science to commercialize SER-109 if it can win FDA approval. SER-109 is an...
Via
Benzinga
Exposures
Product Safety
Seres Therapeutics Gets FDA Green Signal to Start SER-155 Human Trials
June 01, 2021
The FDA has signed off Seres Therapeutics Inc's (NASDAQ: MCRB) Investigational New Drug (IND) application for SER-155 to initiate Phase 1 trial. SER-155 is a...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Tuesday's Intraday Session
May 11, 2021
Gainers Applied DNA Sciences (NASDAQ:APDN) shares rose 27.71% to $7.42 during Tuesday's regular session. Trading volume for Applied DNA Sciences's stock is 7.2...
Via
Benzinga
Seres Therapeutics: Q1 Earnings Insights
May 04, 2021
Shares of Seres Therapeutics (NASDAQ:MCRB) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share were down 39.29% year over year to ($0...
Via
Benzinga
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
May 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Earnings Scheduled For May 4, 2021
May 04, 2021
Companies Reporting Before The Bell • Lancaster Colony (NASDAQ:LANC) is likely to report quarterly earnings at $1.24 per share on revenue of $340.02 million. •...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.